Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

436

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
OverweightObesity
Interventions
DEVICE

Gelesis100

DEVICE

placebo

Trial Locations (36)

10065

Investigative Site, New York

17822

Investigative Site, Danville

20097

Investigative Site, Milan

23294

Investigative Site, Richmond

23606

Investigative Site, Norfolk

27612

Investigative Site, Raleigh

31008

Investigative Site, Pamplona

32205

Investigative Site, Jacksonville

33143

Investigative Site, Miami

37203

Investigative Site, Nashville

43212

Investigative Site, Columbus

43213

Investigative Site, Columbus

45219

Investigative Site, Cincinnati

60208

Investigative Site, Chicago

70808

Investigative Site, Baton Rouge

75246

Investigative Site, Dallas

78681

Investigative Site, Round Rock

80045

Investigative Site, Aurora

80131

Investigative Site, Naples

83642

Investigative Site, Boise

84088

Investigative Site, West Jordan

89401

Investigative Site, Las Vegas

91307

Investigative Site, West Hills

92103

Investigative Site, San Diego

92780

Investigative Site, Tustin

92801

Investigative Site, Anaheim

94598

Investigative Site, Walnut Creek

02115

Investigative Site, Boston

K1N 6N5

Investigative Site, Ottawa

G1V 0A6

Investigative Site, Québec

500 00

Investigative Site, Hradec

121 08

Investigative Site, Prague

140 00

Investigative Site, Prague

182 00

Investigative Site, Prague

DK-1958

Investigative Site, Copenhagen

00161

Investigative Site, Rome

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gelesis, Inc.

INDUSTRY

NCT02307279 - Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes | Biotech Hunter | Biotech Hunter